Skip to main content
×
Home

Intestinal bile acid receptors are key regulators of glucose homeostasis

  • Mohamed-Sami Trabelsi (a1), Sophie Lestavel (a2), Bart Staels (a2) and Xavier Collet (a1)
Abstract

In addition to their well-known function as dietary lipid detergents, bile acids have emerged as important signalling molecules that regulate energy homeostasis. Recent studies have highlighted that disrupted bile acid metabolism is associated with metabolism disorders such as dyslipidaemia, intestinal chronic inflammatory diseases and obesity. In particular, type 2 diabetes (T2D) is associated with quantitative and qualitative modifications in bile acid metabolism. Bile acids bind and modulate the activity of transmembrane and nuclear receptors (NR). Among these receptors, the G-protein-coupled bile acid receptor 1 (TGR5) and the NR farnesoid X receptor (FXR) are implicated in the regulation of bile acid, lipid, glucose and energy homeostasis. The role of these receptors in the intestine in energy metabolism regulation has been recently highlighted. More precisely, recent studies have shown that FXR is important for glucose homeostasis in particular in metabolic disorders such as T2D and obesity. This review highlights the growing importance of the bile acid receptors TGR5 and FXR in the intestine as key regulators of glucose metabolism and their potential as therapeutic targets.

Copyright
Corresponding author
* Corresponding author: M.-S. Trabelsi, email sami.trabelsi@inserm.fr
References
Hide All
1. Pandak WM, Bohdan P, Franklund C et al. (2001) Expression of sterol 12alpha-hydroxylase alters bile acid pool composition in primary rat hepatocytes and in vivo . Gastroenterology 120, 18011809.
2. Li-Hawkins J, Gåfvels M, Olin M et al. (2002) Cholic acid mediates negative feedback regulation of bile acid synthesis in mice. J Clin Invest 110, 11911200.
3. Schwarz M, Russell DW, Dietschy JM et al. (2001) Alternate pathways of bile acid synthesis in the cholesterol 7 alpha-hydroxylase knockout mouse are not upregulated by either cholesterol or cholestyramine feeding. J Lipid Res 42, 15941603.
4. Luchoomun J & Hussain MM (1999) Assembly and secretion of chylomicrons by differentiated Caco-2 cells. Nascent triglycerides and preformed phospholipids are preferentially used for lipoprotein assembly. J Biol Chem 274, 1956519572.
5. Hagenbuch B & Meier PJ (2004) Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflüg Arch 447, 653665.
6. Mazuy C, Helleboid A, Staels B et al. (2015) Nuclear bile acid signaling through the farnesoid X receptor. Cell Mol Life Sci 72, 16311650.
7. Prawitt J, Caron S & Staels B (2011) Bile acid metabolism and the pathogenesis of type 2 diabetes. Curr Diab Rep 11, 160166.
8. de Aguiar Vallim TQ, Tarling EJ & Edwards PA (2013) Pleiotropic roles of bile acids in metabolism. Cell Metab 17, 657669.
9. Dey N, Wagner VE, Blanton LV et al. (2015) Regulators of gut motility revealed by a gnotobiotic model of diet-microbiome interactions related to travel. Cell 163, 95107.
10. Rolo AP, Palmeira CM, Holy JM et al. (2004) Role of mitochondrial dysfunction in combined bile acid-induced cytotoxicity: the switch between apoptosis and necrosis. Toxicol Sci 79, 196204.
11. Morgan WA, Nk T & Ding Y (2008) The use of high performance thin-layer chromatography to determine the role of membrane lipid composition in bile salt-induced kidney cell damage. J Pharmacol Toxicol Methods 57, 7073.
12. Perez M-J & Briz O (2009) Bile-acid-induced cell injury and protection. World J Gastroenterol 15, 16771689.
13. Prawitt J & Staels B (2010) Bile acid sequestrants: glucose-lowering mechanisms. Metab Syndr Relat Disord 8, Suppl. 1, S3S8.
14. Kawamata Y, Fujii R, Hosoya M et al. (2003) A G protein-coupled receptor responsive to bile acids. J Biol Chem 278, 94359440.
15. Maruyama T, Tanaka K, Suzuki J et al. (2006) Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice. J Endocrinol 191, 197205.
16. Watanabe M, Houten SM, Mataki C et al. (2006) Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439, 484489.
17. Briere DA, Ruan X, Cheng CC et al. (2015) novel small molecule agonist of tgr5 possesses anti-diabetic effects but causes gallbladder filling in mice. PLoS ONE 10, e0136873.
18. Harach T, Pols TWH, Nomura M et al. (2012) TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci Rep 2, 430.
19. Li T, Holmstrom SR, Kir S et al. (2011) The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. Mol Endocrinol 25, 10661071.
20. Donepudi AC, Boehme S, Li F et al. (2016) G-protein-coupled bile acid receptor plays a key role in bile acid metabolism and fasting-induced hepatic steatosis in mice. Hepatology. [Epublication ahead of print version]
21. Lou G, Ma X, Fu X et al. (2014) GPBAR1/TGR5 mediates bile acid-induced cytokine expression in murine Kupffer cells. PLoS ONE 9, e93567.
22. Alemi F, Poole DP, Chiu J et al. (2013) The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. Gastroenterology 144, 145154.
23. Kidd M, Modlin IM, Gustafsson BI et al. (2008) Luminal regulation of normal and neoplastic human EC cell serotonin release is mediated by bile salts, amines, tastants, and olfactants. Am J Physiol Gastrointest Liver Physiol 295, G260G272.
24. Grider JR (2003) Neurotransmitters mediating the intestinal peristaltic reflex in the mouse. J Pharmacol Exp Ther 307, 460467.
25. Grider JR, Piland BE, Gulick MA et al. (2006) Brain-derived neurotrophic factor augments peristalsis by augmenting 5-HT and calcitonin gene-related peptide release. Gastroenterology 130, 771780.
26. Seol W, Choi HS & Moore DD (1995) Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors. Mol Endocrinol 9, 7285.
27. Forman BM, Goode E, Chen J et al. (1995) Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81, 687693.
28. Wang H, Chen J, Hollister K et al. (1999) Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 3, 543553.
29. Mangelsdorf DJ, Thummel C, Beato M et al. (1995) The nuclear receptor superfamily: the second decade. Cell 83, 835939.
30. Zhang Y, Kast-Woelbern HR & Edwards PA (2003) Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J Biol Chem 278, 104110.
31. Hu X, Bonde Y, Eggertsen G et al. (2014) Muricholic bile acids are potent regulators of bile acid synthesis via a positive feedback mechanism. J Intern Med 275, 2738.
32. Sayin SI, Wahlström A, Felin J et al. (2013) Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 17, 225235.
33. Campana G, Pasini P, Roda A et al. (2005) Regulation of ileal bile acid-binding protein expression in Caco-2 cells by ursodeoxycholic acid: role of the farnesoid X receptor. Biochem Pharmacol 69, 17551763.
34. Sinal CJ, Tohkin M, Miyata M et al. (2000) Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102, 731744.
35. Lu TT, Makishima M, Repa JJ et al. (2000) Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 6, 507515.
36. Sanyal S, Båvner A, Haroniti A et al. (2007) Involvement of corepressor complex subunit GPS2 in transcriptional pathways governing human bile acid biosynthesis. Proc Natl Acad Sci USA 104, 1566515770.
37. Lefebvre P, Cariou B, Lien F et al. (2009) Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 89, 147191.
38. Chen F, Ma L, Dawson PA et al. (2003) Liver receptor homologue-1 mediates species- and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter. J Biol Chem 278, 1990919916.
39. Hwang ST, Urizar NL, Moore DD et al. (2002) Bile acids regulate the ontogenic expression of ileal bile acid binding protein in the rat via the farnesoid X receptor. Gastroenterology 122, 14831492.
40. Boyer JL, Trauner M, Mennone A et al. (2006) Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol 290, G1124G1130.
41. Lee H, Zhang Y, Lee FY et al. (2006) FXR regulates organic solute transporters alpha and beta in the adrenal gland, kidney, and intestine. J Lipid Res 47, 201214.
42. Markan KR & Potthoff MJ (2016) Metabolic fibroblast growth factors (FGFs): mediators of energy homeostasis. Semin Cell Dev Biol 53, 8593.
43. Owen BM, Mangelsdorf DJ & Kliewer SA (2015) Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. Trends Endocrinol Metab 26, 2229.
44. Baggio LL & Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 21312157.
45. Ward C (2016) Metabolism, insulin and other hormones – Diapedia (Internet). Available from http://www.diapedia.org/5105252812/rev/7 (accessed August 2016).
46. Parker HE, Adriaenssens A, Rogers G et al. (2012) Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion. Diabetologia 55, 24452455.
47. Reimann F, Habib AM, Tolhurst G et al. (2008) Glucose sensing in L cells: a primary cell study. Cell Metab 8, 532539.
48. Gorboulev V, Schürmann A, Vallon V et al. (2012) Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61, 187196.
49. Kuhre RE, Frost CR, Svendsen B et al. (2015) Molecular mechanisms of glucose-stimulated GLP-1 secretion from perfused rat small intestine. Diabetes 64, 370382.
50. Daoudi M, Hennuyer N, Borland MG et al. (2011) PPARβ/δ activation induces enteroendocrine L cell GLP-1 production. Gastroenterology 140, 15641574.
51. Trabelsi M-S, Daoudi M, Prawitt J et al. (2015) Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat Commun 6, 7629.
52. Habib AM, Richards P, Cairns LS et al. (2012) Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. Endocrinology 153, 30543065.
53. Filhoulaud G, Guilmeau S, Dentin R et al. (2013) Novel insights into ChREBP regulation and function. Trends Endocrinol Metab 24, 257268.
54. Vallim TQ & Edwards PA (2009) Bile acids have the gall to function as hormones. Cell Metab 10, 162164.
55. Thomas C, Gioiello A, Noriega L et al. (2009) TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 10, 167177.
56. Potthoff MJ, Potts A, He T et al. (2013) Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. Am J Physiol Gastrointest Liver Physiol 304, G371G380.
57. Bala V, Rajagopal S, Kumar DP et al. (2014) Release of GLP-1 and PYY in response to the activation of G protein-coupled bile acid receptor TGR5 is mediated by Epac/PLC-ε pathway and modulated by endogenous H2S. Front Physiol 5, 420.
58. Brighton CA, Rievaj J, Kuhre RE et al. (2015) Bile acids trigger GLP-1 release predominantly by accessing basolaterally located G protein-coupled bile acid receptors. Endocrinology 156, 39613970.
59.World Health Organization (2016) Obesity and Overweight: Fact Sheet. http://www.who.int/mediacentre/factsheets/fs311/en/ (accessed September 2016).
60.World Health Organization (2016) Diabetes: Fact sheet http://www.who.int/mediacentre/factsheets/fs312/en/ (accessed September 2016).
61. Huang PL (2009) A comprehensive definition for metabolic syndrome. Dis Model Mech 2, 231237.
62. Bennion LJ & Grundy SM (1977) Effects of diabetes mellitus on cholesterol metabolism in man. N Engl J Med 296, 13651371.
63. Abrams JJ, Ginsberg H & Grundy SM (1982) Metabolism of cholesterol and plasma triglycerides in nonketotic diabetes mellitus. Diabetes 31, 903910.
64. Brufau G, Stellaard F, Prado K et al. (2010) Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology 52, 14551464.
65. Suhre K, Meisinger C, Döring A et al. (2010) Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS ONE 5, e13953.
66. Sonne DP, van Nierop FS, Kulik W et al. (2016) Postprandial plasma concentrations of individual bile acids and FGF-19 in patients with type 2 diabetes. J Clin Endocrinol Metab 101, 30023009.
67. Haeusler RA, Astiarraga B, Camastra S et al. (2013) Human insulin resistance is associated with increased plasma levels of 12α-hydroxylated bile acids. Diabetes 62, 41844191.
68. Goncalves D, Barataud A, De Vadder F et al. (2015) Bile routing modification reproduces key features of gastric bypass in rat. Ann Surg 262, 10061015.
69. Flynn CR, Albaugh VL, Cai S et al. (2015) Bile diversion to the distal small intestine has comparable metabolic benefits to bariatric surgery. Nat Commun 6, 7715.
70. Pierre JF, Martinez KB, Ye H et al. (2016) Activation of bile acid signaling improves metabolic phenotypes in high-fat diet-induced obese mice. Am J Physiol Gastrointest Liver Physiol 311, G286G304.
71. Kohli R, Kirby M, Setchell KDR et al. (2010) Intestinal adaptation after ileal interposition surgery increases bile acid recycling and protects against obesity-related comorbidities. Am J Physiol Gastrointest Liver Physiol 299, G652G660.
72. Wu T, Bound MJ, Standfield SD et al. (2013) Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans. Diab Obes Metab 15, 474477.
73. Adrian TE, Gariballa S, Parekh KA et al. (2012) Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers. Diabetologia 55, 23432347.
74. Bianco AC, Maia AL, da Silva WS et al. (2005) Adaptive activation of thyroid hormone and energy expenditure. Biosci Rep 25, 191208.
75. Vassileva G, Hu W, Hoos L et al. (2010) Gender-dependent effect of Gpbar1 genetic deletion on the metabolic profiles of diet-induced obese mice. J Endocrinol 205, 225232.
76. Zhang Y, Lee FY, Barrera G et al. (2006) Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA 103, 10061111.
77. Cariou B, van Harmelen K, Duran-Sandoval D et al. (2006) The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 281, 1103911049.
78. Ma Y, Huang Y, Yan L et al. (2013) Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance. Pharm Res 30, 14471457.
79. Caron S, Huaman Samanez C, Dehondt H et al. (2013) Farnesoid X receptor inhibits the transcriptional activity of carbohydrate response element binding protein in human hepatocytes. Mol Cell Biol 33, 22022211.
80. Watanabe M, Horai Y, Houten SM et al. (2011) Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. J Biol Chem 286, 2691326920.
81. Fang S, Suh JM, Reilly SM et al. (2015) Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 21, 159165.
82. Schonewille M, de Boer JF & Groen AK (2016) Bile salts in control of lipid metabolism. Curr Opin Lipidol 27, 295301.
83. van Dijk TH, Grefhorst A, Oosterveer MH et al. (2009) An increased flux through the glucose 6-phosphate pool in enterocytes delays glucose absorption in Fxr−/− mice. J Biol Chem 284, 1031510323.
84. Prawitt J, Abdelkarim M, Stroeve JHM et al. (2011) Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes 60, 18611871.
85. Bjursell M, Wedin M, Admyre T et al. (2013) Ageing Fxr deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH. PLoS ONE 8, e64721.
86. Ryan KK, Tremaroli V, Clemmensen C et al. (2014) FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 509, 183188.
87. Parséus A, Sommer N, Sommer F et al. (2016) Microbiota-induced obesity requires farnesoid X receptor. Gut [Epublication ahead of print version].
88. Jiang C, Xie C, Lv Y et al. (2015) Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun 6, 10166.
89. Li F, Jiang C, Krausz KW et al. (2013) Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun 4, 2384.
90. Herrema H, Meissner M, van Dijk TH et al. (2010) Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor- and liver X receptor alpha-controlled metabolic pathways in mice. Hepatology 51, 806816.
91. Garg A & Grundy SM (1994) Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 121, 416422.
92. Staels B & Kuipers F (2007) Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 67, 13831392.
93. Prawitt J, Caron S & Staels B (2014) Glucose-lowering effects of intestinal bile acid sequestration through enhancement of splanchnic glucose utilization. Trends Endocrinol Metab 25, 235244.
94. Beysen C, Murphy EJ, Deines K et al. (2012) Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia 55, 432442.
95. Shang Q, Saumoy M, Holst JJ et al. (2010) Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. Am J Physiol Gastrointest Liver Physiol 298, G419G424.
96. Chen L, McNulty J, Anderson D et al. (2010) Cholestyramine reverses hyperglycemia and enhances glucose-stimulated glucagon-like peptide 1 release in Zucker diabetic fatty rats. J Pharmacol Exp Ther 334, 164170.
97. Bäckhed F, Manchester JK, Semenkovich CF et al. (2007) Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA 104, 979984.
98. Wichmann A, Allahyar A, Greiner TU et al. (2013) Microbial modulation of energy availability in the colon regulates intestinal transit. Cell Host Microbe 14, 582590.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Proceedings of the Nutrition Society
  • ISSN: 0029-6651
  • EISSN: 1475-2719
  • URL: /core/journals/proceedings-of-the-nutrition-society
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 14
Total number of PDF views: 58 *
Loading metrics...

Abstract views

Total abstract views: 308 *
Loading metrics...

* Views captured on Cambridge Core between 16th November 2017 - 19th November 2017. This data will be updated every 24 hours.